Monday, May 15, 2017 11:22:56 AM
Live Call:
U.S. 877-866-5534
International 346-406-0930
Passcode 20313217
Live Webcast:
AmpliPhi IR Website
The webcast replay will be available approximately 2 hours
after completion of the call and will be archived for 30 days.
Replay: U.S. 855-859-2056
International 404-537-3406
Passcode 20313217
The replay will be available for 48 hours starting approximately
2 hours after completion of the call.
About AmpliPhi Biosciences
AmpliPhi Biosciences Corporation is a biotechnology company pioneering the development and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. In May 2017, AmpliPhi announced a new strategic emphasis on developing precisely targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. AmpliPhi has reported results from two Phase 1 clinical trials of AB-SA01, one for the treatment of S. aureus in chronic rhinosinusitis patients (safety and preliminary efficacy) and one to evaluate the safety of AB-SA01 when administered topically to the intact skin of healthy adults.
Contact:
At the Company:
AmpliPhi Biosciences
Matthew Dansey, (858) 800-4869
md@ampliphibio.com
or
Investor Relations:
LHA
Jody Cain, (310) 691-7100
jcain@lhai.com
Recent ARMP News
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/04/2024 10:35:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 09:03:37 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/23/2024 09:17:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 02:55:39 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 02:55:01 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 02:54:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 02:54:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 02:54:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 02:53:36 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 02:53:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 02:53:27 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 11/15/2023 10:24:56 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/22/2023 11:17:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 12:00:15 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 11:30:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 11:15:29 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/03/2023 08:35:42 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/03/2023 08:34:24 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 07/24/2023 08:30:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2023 08:30:30 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 07/11/2023 12:27:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2023 12:15:48 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM